Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Suita, Japan.
Circ J. 2012;76(12):2855-62. doi: 10.1253/circj.cj-12-0208. Epub 2012 Aug 11.
Supraventricular and ventricular tachyarrhythmias (SVT, VT) are major concerns after repair of tetralogy of Fallot (TOF). This study evaluated the impact of comprehensive treatment, including hemodynamic interventions such as surgery, catheter-based intervention and pacemaker implantation (PMI), on tachyarrhythmia in repaired TOF patients.
Of 66 repaired TOF patients with tachyarrhythmia (age at onset, 23±11 years), 29 patients had sustained SVT, 21 had sustained or non-sustained VT, and 16 had both (SVT+VT). Successful treatment with catheter-directed ablation and/or anti-arrhythmic drugs (AADs) alone was achieved in 31 (69%) and partially achieved in 6 (13%) of 45 patients. Surgery, catheter-based intervention, and/or PMI were performed in 21 (32%) of 66 patients and resulted in complete control of the arrhythmia in 8 (38%) and partial control in 7 (33%) of these 21 patients, 20 (95%) of whom were receiving AADs. Patients with successfully controlled tachyarrhythmia in response to catheter ablation and/or AADs without hemodynamic intervention had a significantly higher probability of absence of sinus node dysfunction (odds ratio [OR], 23.2; 95% confidence interval [CI], 1.8-845.2; P=0.02) and lone intra-atrial reentrant tachycardia (OR, 12.4; 95% CI: 1.3-278.7; P=0.03).
Hemodynamic interventions resulted in an improvement in outcomes in repaired TOF patients with tachyarrhythmia. To effectively manage intractable tachyarrhythmia with hemodynamic abnormalities, it is essential to understand hemodynamics and consider hemodynamic intervention.
室上性和室性心动过速(SVT、VT)是法洛四联症(TOF)修复后的主要关注点。本研究评估了综合治疗(包括手术、基于导管的介入和起搏器植入(PMI)等血流动力学干预)对修复后的 TOF 患者心动过速的影响。
在 66 例心动过速的修复 TOF 患者(发病时年龄,23±11 岁)中,29 例患者有持续性 SVT,21 例患者有持续性或非持续性 VT,16 例患者有 SVT+VT。单独经导管消融和/或抗心律失常药物(AAD)治疗成功的患者有 31 例(69%),部分成功的患者有 6 例(13%)。66 例患者中的 21 例(32%)进行了手术、基于导管的介入和/或 PMI,其中 8 例(38%)心律失常完全得到控制,7 例(33%)部分得到控制,这些患者中有 20 例(95%)正在服用 AAD。在未进行血流动力学干预的情况下,通过导管消融和/或 AAD 成功控制心动过速的患者,窦房结功能障碍(比值比 [OR],23.2;95%置信区间 [CI],1.8-845.2;P=0.02)和孤立性房内折返性心动过速(OR,12.4;95%CI:1.3-278.7;P=0.03)的可能性显著更高。
血流动力学干预改善了心动过速的修复 TOF 患者的结局。为了有效管理伴有血流动力学异常的难治性心动过速,必须了解血流动力学并考虑血流动力学干预。